Practical Management of Early Stage HER2+ Breast Cancer

Video

Nurse practitioners provide insight on issues surrounding the administration of dual HER2-targeted therapy in the neoadjuvant/adjuvant setting and counseling patients on common AEs associated with trastuzumab-pertuzumab for the treatment of HER2+ breast cancer.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Image of a woman with light brown hair wearing glasses with a blue background
Image of a woman wearing glasses in front of a blue background
Image of a woman with glasses in front of a blue background
Image of a man in a suit smiling in front of an Oncology Nursing News background
Related Content
Photo of a woman with brown hair and bangs, surrounded by a blue border

AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

Michelle Kirschner, RN, MSN, ACNP, APRN-BC
June 30th 2025
Article

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Anatomical image of a person with a breast tumor

T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

Tim Cortese
June 11th 2025
Article

T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Lindsay Fischer
January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

AI-generated graphic of cancer cells

T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors

Chris Ryan
June 2nd 2025
Article

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.

Illustration of two people in lab coats using scientific instruments with a breast icon in the background

Camizestrant/CDK4/6 Inhibition Boosts PFS in ESR1+ Advanced Breast Cancer

Caroline Seymour
June 2nd 2025
Article

Camizestrant plus CDK4/6 inhibition improved PFS vs standard care in patients with ER+/HER2– advanced breast cancer and emergent ESR1 mutations.